HomeCompareIAA vs ABBV

IAA vs ABBV: Dividend Comparison 2026

IAA yields 5.01% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $74.5K in total portfolio value
10 years
IAA
IAA
● Live price
5.01%
Share price
$39.89
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$27.8K
Annual income
$690.95
Full IAA calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — IAA vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIAAABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IAA + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
IAA pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IAA
Annual income on $10K today (after 15% tax)
$426.17/yr
After 10yr DRIP, annual income (after tax)
$587.31/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $20,468.70/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IAA + ABBV for your $10,000?

IAA: 50%ABBV: 50%
100% ABBV50/50100% IAA
Portfolio after 10yr
$65.1K
Annual income
$12,731.35/yr
Blended yield
19.57%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

IAA
Analyst Ratings
4
Buy
4
Hold
1
Sell
Consensus: Buy
Price Target
$50.00
+25.3% upside vs current
Range: $50.00 — $50.00
Altman Z
2.6
Piotroski
8/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IAA buys
1
ABBV buys
0
PoliticianChamberTickerTypeAmountDate
Ro Khanna🏢 House$IAA▼ Sell$1,001 - $15,0002022-05-10
Lois Frankel🏢 House$IAA▼ Sell$1,001 - $15,0002022-03-08
Ro Khanna🏢 House$IAA▲ Buy$1,001 - $15,0002022-02-14
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIAAABBV
Forward yield5.01%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$27.8K$102.3K
Annual income after 10y$690.95$24,771.77
Total dividends collected$6.0K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy
Analyst price target$50.00$256.15

Year-by-year: IAA vs ABBV ($10,000, DRIP)

YearIAA PortfolioIAA Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,201$501.38$11,550$430.00$349.00ABBV
2$12,510$524.87$13,472$627.96$962.00ABBV
3$13,934$547.86$15,906$926.08$2.0KABBV
4$15,480$570.28$19,071$1,382.55$3.6KABBV
5$17,155$592.09$23,302$2,095.81$6.1KABBV
6$18,969$613.26$29,150$3,237.93$10.2KABBV
7$20,931$633.75$37,536$5,121.41$16.6KABBV
8$23,050$653.54$50,079$8,338.38$27.0KABBV
9$25,336$672.61$69,753$14,065.80$44.4KABBV
10$27,800$690.95$102,337$24,771.77$74.5KABBV

IAA vs ABBV: Complete Analysis 2026

IAAStock

IAA, Inc. operates a digital marketplace that connects vehicle buyers and sellers. The company's platform facilitates the marketing and sale of total loss, damaged, and low-value vehicles for a range of sellers. It provides buyers with various bidding/buying digital channels, vehicle merchandising, evaluation services and online bidding tools, and replacement part inventory. The company serves a buyer base and spectrum of sellers, including insurance companies, dealerships, fleet lease and rental car companies, and charitable organizations. It has approximately 200 facilities in the United States, Canada, and the United Kingdom. IAA, Inc. was founded in 1982 and is headquartered in Westchester, Illinois.

Full IAA Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this IAA vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IAA vs SCHDIAA vs JEPIIAA vs OIAA vs KOIAA vs MAINIAA vs JNJIAA vs MRKIAA vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.